3653 results for «302»
3653 results
TAVI in a patient with heavily calcified valve anatomy - LIVE case
18 Feb 2023 – From PCR Tokyo Valves 2023
An 80-year-old male with chronic kidney disease and interstitial pneumonia treated under steroids presented a symptomatic severe aortic stenosis with massive calcifications on the valves and only on the valves (not the LVOT).
Watch the operators implant a Sapien 3 23 mm (-1cc) with a predilatation (Balloon...
Future devices and techniques
19 Feb 2023 – From PCR Tokyo Valves 2023
In this session, find out more about TMVR device options and trial updates, a case of severe mitral regurgitation treated with TMVR, ongoing trials and future innovations regarding transcatheter tricuspid valve repair and replacement, and much more!
My worst nightmare in TAVI
Listen to our experts share their most nightmarish TAVI cases and follow the debate around their treatments. For instance, would you make the same choices when faced with a 76-year-old female patient diagnosed as severe AS, transferred for SAVR/TAVI, who got a new Abif and cardiogenic...
PCR Tokyo Valves 2023 Closing Ceremony
19 Feb 2023 – From PCR Tokyo Valves 2023
This closing ceremony of the 2023 edition of the PCR Tokyo Valves is the occasion to unveil the results of the best abstract and best case competitions and to congratulate the finalists. It is also the moment to take stock of this excellent edition, to thank...
TAVI in small annulus and coronary artery disease - Session with LIVE case
19 Feb 2023 – From PCR Tokyo Valves 2023
Watch the complex case of an 84-year-old woman with hypertension, type 2 diabetes and coronary artery disease who presented with worsening NYHA class II-III exertional dyspnoea, but no angina, and find out how she was treated LIVE.
The optimal first valve choice for all patients with aortic stenosis
18 Feb 2023 – From PCR Tokyo Valves 2023
How have advances in TAVI impacted the lifetime journey of patients with aortic stenosis? Join this panel of experts as they discuss the importance of optimizing the first procedure and the key issues regarding treatment options in patients with bioprosthetic valve deterioration of transcatheter heart valve.
How to optimise the lifetime management of TAVI patients with long-life expectancy?
18 Feb 2023 – From PCR Tokyo Valves 2023
This session addresses three essential elements of a successful TAVI procedure: the impact of valve design on long-term durability, how to mitigate the risk of paravalvular leakage, and the importance of the possibility for coronary access after TAVI.
Remaining unmet needs and strategies in TAVI
19 Feb 2023 – From PCR Tokyo Valves 2023
This session focuses on valve design and durability performance in TAVI for patients with aortic stenosis, and the way it impacts future patient outcomes.
Efficacy and safety of Edoxaban in anticoagulant therapy early after surgical bioprosthetic valve replacement: ENBALV trial
16 Nov 2024
Edoardo Zancanaro provides his take on the ENBALV trial presented by Chisato Izumi at AHA 2024 in Chicago.

Author
On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial
05 Mar 2023
Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).

Author
Transcatheter edge-to-edge repair of functional mitral regurgitation in heart failure: Final five-year results from the COAPT Trial
06 Mar 2023
Alex Sticchi & Jonathan Curio provide their take on the clinical trial presented by Gregg W. Stone at the American College of Cardiology Scientific Sessions (ACC.23/WCC).

Author

Author
ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation
31 Aug 2021
Following the Hot Line session of the ESC Congress 2021 presented by George Dangas (New-York, USA), Daniele Giacoppo offers us a condensed version of this study.

Author
Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR
29 Mar 2025
Daniele Giacoppo and Nicola Ammirabile provide their take on the main results of the HOST-BR trial, presented by Hyo-Soo Kim at ACC.25 in Chicago.

Author

Author